NYSE:TFX - Teleflex Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$237.89 +2.89 (+1.23 %)
(As of 08/16/2018 12:02 PM ET)
Previous Close$235.51
Today's Range$234.99 - $238.91
52-Week Range$203.70 - $288.78
Volume4,518 shs
Average Volume297,680 shs
Market Capitalization$10.45 billion
P/E Ratio28.06
Dividend Yield0.59%
Beta1.2
Teleflex logoTeleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. The company also provides interventional access products that are used in dialysis, oncology, and critical care therapies; and cardiac care products, such as diagnostic and intra-aortic balloon catheters, and capital equipment. In addition, it offers anesthesia products, such as pain management products for use in surgical and obstetric procedures; airway management products and related devices for use in pre-hospital emergency and hospital settings; and other pre-hospital emergency products. Further, the company offers surgical products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems, Percutaneous Surgical Systems, Weck Vista bladeless access ports, Deknatel sutures, and Pilling and Kmedic surgical instruments; products for use in acute care settings for diagnostic and therapeutic procedures, and in general and specialty surgical applications; and single-use respiratory, urology, and interventional urology products. Additionally, it provides devices and instruments for other medical device manufacturers, such as custom-engineered extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets and kits, sutures, performance fibers, and bioresorbable resins and fibers. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.

Receive TFX News and Ratings via Email

Sign-up to receive the latest news and ratings for TFX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:TFX
CUSIP87936910
Phone610-225-6800

Debt

Debt-to-Equity Ratio0.88
Current Ratio2.21
Quick Ratio1.45

Price-To-Earnings

Trailing P/E Ratio28.06
Forward P/E Ratio24.23
P/E Growth1.6

Sales & Book Value

Annual Sales$2.15 billion
Price / Sales5.08
Cash Flow$12.7282 per share
Price / Cash18.69
Book Value$53.95 per share
Price / Book4.41

Profitability

EPS (Most Recent Fiscal Year)$8.40
Net Income$152.53 million
Net Margins3.78%
Return on Equity17.32%
Return on Assets7.04%

Miscellaneous

Employees14,400
Outstanding Shares45,800,000
Market Cap$10.45 billion

Teleflex (NYSE:TFX) Frequently Asked Questions

What is Teleflex's stock symbol?

Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."

How often does Teleflex pay dividends? What is the dividend yield for Teleflex?

Teleflex declared a quarterly dividend on Thursday, August 2nd. Investors of record on Wednesday, August 15th will be given a dividend of $0.34 per share on Friday, September 14th. This represents a $1.36 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Tuesday, August 14th. View Teleflex's Dividend History.

How were Teleflex's earnings last quarter?

Teleflex Incorporated (NYSE:TFX) announced its quarterly earnings results on Thursday, August, 2nd. The medical technology company reported $2.47 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.41 by $0.06. The medical technology company had revenue of $609.87 million for the quarter, compared to the consensus estimate of $615.97 million. Teleflex had a return on equity of 17.32% and a net margin of 3.78%. The firm's revenue was up 15.4% on a year-over-year basis. During the same period last year, the firm posted $2.04 earnings per share. View Teleflex's Earnings History.

When is Teleflex's next earnings date?

Teleflex is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Teleflex.

What guidance has Teleflex issued on next quarter's earnings?

Teleflex updated its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share (EPS) guidance of $9.70-9.90 for the period, compared to the Thomson Reuters consensus estimate of $9.79. The company issued revenue guidance of $2.45-2.47 billion (+14-15%), compared to the consensus revenue estimate of $2.47 billion.

What price target have analysts set for TFX?

10 Wall Street analysts have issued 1-year price targets for Teleflex's stock. Their predictions range from $253.00 to $317.00. On average, they expect Teleflex's stock price to reach $282.8889 in the next year. This suggests a possible upside of 18.7% from the stock's current price. View Analyst Price Targets for Teleflex.

What is the consensus analysts' recommendation for Teleflex?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teleflex.

What are Wall Street analysts saying about Teleflex stock?

Here are some recent quotes from research analysts about Teleflex stock:
  • 1. Needham & Company LLC analysts commented, "TFX is hosting an analyst day on 5/11/18 in New York. We note that TFX is on track to beat three out of four of its long range plan (LRP) targets (revenue growth, gross margin improvement, operating margin improvement, and free cash flow growth) from its 2015 analyst day. Assuming that TFX updates its prior four targets for 2019-2021, we expect it to target organic revenue growth that is slightly below consensus (~50 bps) and to set targets in line with consensus for the other items. We expect investors to view the revenue growth target at conservative, however, and don’t expect a negative stock reaction. We have also provided a list of ten questions that we think will be important for management to address at the analyst day (see page 2). We expect the analyst day to be a positive catalyst and reiterate our Buy rating." (5/9/2018)
  • 2. According to Zacks Investment Research, "Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. " (10/4/2017)
  • 3. Barclays PLC analysts commented, "XLRS Progressing Slowly with Some Uncertainty. Although top-line safety data from 12 patients in the Phase I/II XLRS dose escalation study did not reveal SAEs and moderate ocular inflammation was considered manageable, the combination of inter-patient and test variability has affected the ability to determine a therapeutic effect. As a result, AGTC plans to expand enrollment and follow the new patients for at least six months." (9/12/2017)

Who are some of Teleflex's key competitors?

Who are Teleflex's key executives?

Teleflex's management team includes the folowing people:
  • Mr. Liam J. Kelly, Pres, CEO & Director (Age 51)
  • Mr. Thomas E. Powell, Exec. VP & CFO (Age 56)
  • Mr. Thomas Anthony Kennedy, Sr. VP of Global Operations (Age 55)
  • Mr. James J. Leyden, VP, Gen. Counsel & Sec. (Age 51)
  • Mr. John R. Deren, VP & Chief Accounting Officer

Has Teleflex been receiving favorable news coverage?

News stories about TFX stock have trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teleflex earned a news and rumor sentiment score of 0.13 on Accern's scale. They also assigned news articles about the medical technology company an impact score of 46.84 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Teleflex.

Who are Teleflex's major shareholders?

Teleflex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.61%), Select Equity Group L.P. (3.59%), American Century Companies Inc. (2.46%), Janus Henderson Group PLC (1.73%), Bank of New York Mellon Corp (1.20%) and Marshall Wace LLP (0.75%). Company insiders that own Teleflex stock include Andrew A Krakauer, Benson Smith, Cameron P Hicks, George Babich Jr, Gretchen R Haggerty, Jeffrey A Graves, John Deren, Stephen K MD Klasko, Stuart A Randle and Thomas E Powell. View Institutional Ownership Trends for Teleflex.

Which major investors are selling Teleflex stock?

TFX stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., FMR LLC, Redmile Group LLC, Citadel Advisors LLC, BlackRock Inc., Janus Henderson Group PLC, Point72 Asset Management L.P. and Rothschild Asset Management Inc.. Company insiders that have sold Teleflex company stock in the last year include Benson Smith, Cameron P Hicks, George Babich Jr, John Deren, Stephen K MD Klasko and Thomas E Powell. View Insider Buying and Selling for Teleflex.

Which major investors are buying Teleflex stock?

TFX stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Jennison Associates LLC, Mar Vista Investment Partners LLC, Orbimed Advisors LLC, Bank of Montreal Can, Davis R M Inc., Russell Investments Group Ltd. and Icon Advisers Inc. Co.. Company insiders that have bought Teleflex stock in the last two years include Andrew A Krakauer and Gretchen R Haggerty. View Insider Buying and Selling for Teleflex.

How do I buy shares of Teleflex?

Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teleflex's stock price today?

One share of TFX stock can currently be purchased for approximately $238.39.

How big of a company is Teleflex?

Teleflex has a market capitalization of $10.45 billion and generates $2.15 billion in revenue each year. The medical technology company earns $152.53 million in net income (profit) each year or $8.40 on an earnings per share basis. Teleflex employs 14,400 workers across the globe.

How can I contact Teleflex?

Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at 610-225-6800 or via email at [email protected]


MarketBeat Community Rating for Teleflex (NYSE TFX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  612
MarketBeat's community ratings are surveys of what our community members think about Teleflex and other stocks. Vote "Outperform" if you believe TFX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TFX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.